Assistant prof @SylvesterCancer focused on gastric & esophageal cancer | Trained @MDAndersonNews @IMResidencyDuke & @UFMedicine | Wife & Mom | Go gators! 🐊
Miami, FL
Joined January 2020
- Tweets617
- Following752
- Followers920
- Likes6.3K
Cindy M. Pabon, MD retweeted
🟪Oral abstracts #ESMOGI26 @myESMO
Gastric/gastroesophageal
#cancer #oncology #MedX #GI #gastrointestinal #gastric #esophageal @OncoAlert
Cindy M. Pabon, MD retweeted
Good morning from Hollywood, FL. At 65F this is the best time of year! We are hiring by the way! If you do GI, NET or head and neck (and others) let me know @SylvesterCancer @univmiami @ASCO
@uicc @myESMO @IASLC
Cindy M. Pabon, MD retweeted
Pleased to share our ongoing phase II TNT protocol (FLOT, pembro, short RT) for resectable GEJ adenocarcinoma, integrating whole-genome ctDNA to support clinical CR-based organ preservation sciencedirect.com/science/ar… @myESMO @oncodaily @OncoAlert
Cindy M. Pabon, MD retweeted
Are you an oncology attending—anywhere in the world? 🌍
Join The Hidden Struggle Study exploring anxiety, depression & burnout among oncology physicians.
🧠 Fill a short survey & make your voice count.
DM or email [email protected] for the form.
#PhysicianWellbeing
Cindy M. Pabon, MD retweeted
Pleased to share our experience of zolbetuximab induced gastritis @myESMO @ESMO_Open More anorexia & albumin decline in diffuse gastritis, yet reversible without discontinuation. Careful differentiation with gastritis vs disease progression needed. sciencedirect.com/science/ar…
🧪 Early-onset gastritis with ZOLBE
📊 CLDN18.2⁺ GC, 1L CT + ZOLBE (N=58)
⚠️ Gastritis in 89.7% (~8 weeks): erythema, exudate, edema
🌐 Mostly diffuse, multi-region (76.9%, 90.4%)
📌 Linked to anorexia and ↓albumin, improved without treatment cessation
👉 doi.org/10.1016/j.esmoop.202…
Cindy M. Pabon, MD retweeted
We have an unexpected opening in our gastrointestinal pathology fellowship for 2026-2027 at the University of Miami.
If you are interested, please contact [email protected] - include your CV!
Cindy M. Pabon, MD retweeted
📢Gastroesophageal cancers oral abstracts in #ESMO25 @myESMO 👇
#cancer #oncology #GI #gastric #esophageal @OncoAlert @realbowtiedoc @EduardoTB94 @Onco_Cifu88
Cindy M. Pabon, MD retweeted
Pleased to report FGFR2b expression in gastric cancer and relationship with other biomarkers @ESMO_Open @myESMO. The results of bemarituzumab phase 3 studies are awaited.@OncoAlert @oncodaily
sciencedirect.com/science/ar…
Cindy M. Pabon, MD retweeted
Great presentation by @PeterHoseinMD from @SylvesterCancer on pancreas subtypes. Nice to see progress in pancreatic cancer with use of vaccines.
Cindy M. Pabon, MD retweeted
Our very own Dr. Peter Hosein (@PeterHoseinMD) presented "Is Pancreas Subtyping Ready for Prime Time?" at #ASCO25 in a panel discussion focused on #PancreaticCancer research findings. Learn more about our presence: Sylvester.org/ASCO2025.
Cindy M. Pabon, MD retweeted
Join tomorrow morning at 9 AM to learn about #pancreaticcancer subtyping, biomarkers and vaccine research @PeterHoseinMD @SylvesterCancer
Join @PeterHoseinMD tomorrow for a key discussion at #ASCO25 exploring the latest in pancreatic cancer subtyping, biomarkers and vaccine research. Learn how emerging data is shaping clinical practice and pushing precision oncology forward: loom.ly/kD8NHE8.
Cindy M. Pabon, MD retweeted
Have you signed up for #MiamiNights yet?
@SylvesterCancer @asco #asco25
We are hiring - Looking for chiefs for breast and head and neck and oncologists in pretty much all areas
DM me @glopesmd
Abstracts will be released at 5PM EST today!
@ASCO #ASCO25
@SylvesterCancer we are proud to have a number of poster and oral presentations! Follow us for updates and join us at Miami Nights (space is limited, sign up today!)
umiamihealth.org/sylvester-c…
@Latinamd @Jani_Chinmay @JTrentMDPhD @MikkaelSekeres
Cindy M. Pabon, MD retweeted
Stomach cancer is tough to detect early and often diagnosed late. Sylvester experts are tackling it through prevention, biomarker-driven treatment and clinical trials testing new #immunotherapies. Learn more: loom.ly/dNJHPQE. @cmpabon @mbilusic
Cindy M. Pabon, MD retweeted
This study was born from personal experiences and nostalgia
We hoped that these findings would provoke conversations and demand change
I never anticipated the country to go backwards rather than forward
@NarjustFlorezMD @Florez_Lab @AnaVManana @ClaudSVillaCeli @ArunUMahtani
Going Back Home: Understanding the Challenges and Discrimination of Early and Mid-Career International and Puerto Rican Medical Graduates in Oncology Fields in the United States.
Read more: brnw.ch/21wRC5y
#OncTwitter
Cindy M. Pabon, MD retweeted
Did you know that colorectal cancer is one of the most preventable cancers, yet it's still a leading cause of cancer deaths? Regular screenings are key, especially if you're 45 or older.
Our expert Nick Hornstein, MD, PhD, (@GIMedOnc) a medical oncologist specializing in colorectal cancer at @lenoxhill, explains new treatments including advancements in targeted therapies, immunotherapy and minimally invasive surgical techniques, offering new hope for patients. #ColorectalCancerAwarenessMonth
Cindy M. Pabon, MD retweeted
In this review, @cmpabon et al summarize recent data on the optimal preoperative strategy for esophageal or gastro-esophageal junction (GEJ) cancers.
doi.org/10.1093/oncolo/oyae3…
Cindy M. Pabon, MD retweeted
Always great to learn new data in SF and connect with mentors + friends @ASCO GI. Thanks to @ConquerCancerFd for the Merit Award that allowed it to happen. Check out our work describing how ctDNA can be used to track response to IO in pts with dMMR/MSI-H CRC 👇 #GI25
SOOOO proud of our @MDAndersonNews med onc star fellows @MichaelLaPelusa, @KelseyPanMD, & @MirLimMD presenting their research today on #crcsm day at @ASCO #GI25 ! Future is looking bright with their brilliant minds to #endcancer !
Cindy M. Pabon, MD retweeted
#GI25
BREAKWATER
@skopetz changing the paradigm yet again! The true master of BRAF and colorectal targeted therapy.
BRAF+ first line mCRC; n=236 on experimental arm
Enco (BRAF) + Cetux (EGFR)+ FOLFOX
ORR 60% vs 40%!
OS not yet reached!!!
Durable responses and twice as high in experimental arm.
Well tolerated, amazing design to tease out contribution of components.
New standard of care in BRAF+ disease.
@OncoAlert
